donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01652 Fusen Pharmaceutical
0.960
-0.010-1.03%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
-67.74% 0.0759 -62.07% 0.0559 726.56% 0.2352 471% 0.1473
Cash Flow Per Share
-609.35% -0.341 -485.11% -0.3785 85.36% -0.0481 128.72% 0.0983
Operating Income Per Share
-18.02% 0.6127 -3.01% 0.3344 31.46% 0.7474 23.5% 0.3447
Net Asset Per Share
3.29% 1.0455 16.78% 1.0884 7.72% 1.0123 3.74% 0.932
Basic Earning Per Share
-77.12% 0.0245 64.67% 0.0721 36.84% 0.1069 28.4% 0.0438
Diluted  Earning Per Share
-77.12% 0.0245 64.67% 0.0721 36.84% 0.1069 28.4% 0.0438
Profitability
Gross Profit Ratio
0.17% 54.745% 2.84% 55.194% 4.78% 54.650% -1.31% 53.669%
Operating Profit Ratio
6.36% 13.519% 60.71% 21.870% -21.72% 12.711% -17.76% 13.608%
Net Profit Ratio
-66.53% 4.308% 51.41% 20.451% 0.34% 12.872% 11.8% 13.507%
Earning Before Tax Ratio
-61.69% 6.169% 40.15% 23.713% 2.81% 16.104% 20.54% 16.920%
ROE
-76.39% 2.563% 26.34% 6.510% 32.3% 10.855% 36.15% 5.153%
ROA
-77.22% 1.361% 21.22% 3.497% 32.47% 5.978% 38.36% 2.885%
Yield Quality
Operating Profit To Total Profits
177.66% 219.146% 14.67% 92.226% -23.86% 78.927% -31.77% 80.426%
Tax To Total Profits
-50.32% -30.171% 31.8% -13.757% -10.85% -20.071% -44.77% -20.171%
Operating Cash To Total Revenue
-60.64% 12.385% -60.89% 16.713% 528.74% 31.469% 400.41% 42.735%
Capital Structure
Debt Assets Ratio
0.04% 46.992% 2.11% 45.834% 11.69% 46.973% 7.34% 44.886%
Equity Multipler
0.03% 1.883 0.84% 1.8427 7.78% 1.8824 5.14% 1.8273
Debt Equity Ratio
0.08% 88.652% 3.9% 84.616% 22.04% 88.583% 13.33% 81.442%
Current Assets To tatal Assets
-22.76% 41.088% -36.64% 35.859% -7.22% 53.198% -6.43% 56.599%
Non Current Assets To Total Assets
25.87% 58.912% 47.79% 64.141% 9.7% 46.802% 9.85% 43.401%
Current Liabilities To tatal Liabilities
-10.55% 84.010% 0.29% 93.542% 0.82% 93.913% -3.73% 93.274%
Non Current Liabilities To Total Liabilities
162.7% 15.990% -3.99% 6.458% -11.13% 6.087% 116.17% 6.726%
Solvency
Current Ratio
-13.69% 1.0408 -38.13% 0.8364 -17.6% 1.2059 -9.46% 1.3519
Quick Ratio
-21.87% 0.7918 -47.32% 0.6161 -20.31% 1.0134 -7.77% 1.1695
Operating Profit To Current Liabilities
-5.7% 0.1066 29.26% 0.085 -21.28% 0.113 -9.9% 0.0658
Operrating Cash Flow To Current Liabilities
-65.1% 0.0976 -68.55% 0.065 532.28% 0.2798 429.13% 0.2066
Share Equity Without Minority Interest To Total Liabilities
-0.07% 1.1301 -2.88% 1.184 -16.93% 1.1309 -11.4% 1.2192
Operating Cash Flow To Total Liabilities
-68.78% 0.082 -68.46% 0.0608 537.46% 0.2627 416.85% 0.1927
Operating Profit To Total Liabilities
-15.65% 0.0895 29.63% 0.0796 -20.63% 0.1061 -13.26% 0.0614
Operating Capacity
Current Assets Turnover(T)
-10.92% 0.6703 7.23% 0.3847 45.92% 0.7525 41.91% 0.3588
Fixed Assets Turnover(T)
-45.17% 1.5033 -53.68% 0.7711 -4.79% 2.7417 28.99% 1.6647
Total Assets Turnover(T)
-23.98% 0.3154 -16.55% 0.1705 20.62% 0.415 18.05% 0.2044
Growth Ability
Operating Revenue GR 3Y
-254.25% -10.552% -- -20.175% 185.95% 6.841% -- --
Gross Income GR 3Y
-241.81% -10.770% -- -20.422% 183.28% 7.595% -- --
Operating Profit GR 3Y
-18.59% -58.937% -- -36.571% -12.18% -49.696% -- --
EBT GR 3Y
-140.17% -79.408% -- -22.478% 25.66% -33.064% -- --
Net Profit GR 3Y
-130.1% -82.530% -- -17.012% 21.61% -35.867% -- --
Net Profit Attributable To The Parent Company GR 3Y
-194% -82.492% -- -16.818% 36.05% -28.059% -- --
Total Assets GR 3Y
-52.13% 13.909% -- 49.097% 1224.69% 29.054% -- --
Share Equity Without Minority Interest GR 3Y
-94.4% 14.620% -- 203.757% -42.77% 261.162% -- --
Equity GR 3Y
-94.53% 14.005% -- 200.440% -41.57% 256.145% -- --
Total Liabilities GR 3Y
155.29% 13.800% -- -6.541% 51.73% -24.961% -- --
Basic Earning Per Share GR 3Y
-94.21% -85.711% -- -32.450% 21.63% -44.133% -- --
Net Assets Per Share GR 3Y
-- 19.096% -- 136.714% -- -- -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Fusen Pharmaceutical Co., Ltd. is a Chinese company that mainly provides Shuanghuanglian cold medicine. The company is mainly engaged in the R & D, production and sales of a variety of proprietary Chinese medicine and western medicine products for the treatment of cold and fever, cardiovascular disease and anemia. The company's main products include small volume injections, oral liquids, tablets, capsules and granules. The company mainly sells its products in the domestic market.
CEO: Changcheng Cao
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...